Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.

23 Sep, 2021 | 10:12h | UTC

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 

Cluster RCT: Procalcitonin point-of-care testing may reduce antibiotic prescription for patients with suspected lower respiratory tract infection in primary care.

22 Sep, 2021 | 10:01h | UTC

Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial – The BMJ

 

Cluster RCT: Implementing C reactive protein point-of-care testing in nursing homes may reduce antibiotic prescribing for suspected lower respiratory tract infections.

22 Sep, 2021 | 10:02h | UTC

Effect of C reactive protein point-of-care testing on antibiotic prescribing for lower respiratory tract infections in nursing home residents: cluster randomised controlled trial – The BMJ

 

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

21 Sep, 2021 | 09:54h | UTC

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials – European Heart Journal – Cardiovascular Pharmacotherapy

 

Commentary on Twitter (thread – click for more)

 

RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.

17 Sep, 2021 | 10:19h | UTC

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases

 

WSES-AAST Guidelines: Anorectal Emergencies.

17 Sep, 2021 | 10:06h | UTC

Anorectal emergencies: WSES-AAST guidelines – World Journal of Emergency Surgery

 

Guideline: Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome.

17 Sep, 2021 | 10:07h | UTC

Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases – Hepatology

 

ACSM Expert Consensus Statement on Exertional Heat Illness: Recognition, Management, and Return to Activity.

17 Sep, 2021 | 10:03h | UTC

ACSM Expert Consensus Statement on Exertional Heat Illness: Recognition, Management, and Return to Activity – Current Sports Medicine Reports

Related: Guidelines for the Prevention and Treatment of Heat Illness

 

Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.

16 Sep, 2021 | 10:14h | UTC

Vaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine

 

Commentary on Twitter

 

Review | Acute myocarditis: etiology, diagnosis and management.

17 Sep, 2021 | 09:51h | UTC

Acute myocarditis: aetiology, diagnosis and management – Clinical Medicine Journal

 

RCT: Remdesivir does not improve outcomes in patients admitted to hospital with COVID-19.

15 Sep, 2021 | 09:59h | UTC

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial – The Lancet Infectious Diseases

Invited commentary: Remdesivir, on the road to DisCoVeRy – The Lancet Infectious Diseases

Related:

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

WHO Solidarity Trial: Remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19

 

Management of high-risk pulmonary embolism in pregnancy.

15 Sep, 2021 | 08:43h | UTC

Management of high-risk pulmonary embolism in pregnancy – Thrombosis Research

 

‘Do not resuscitate’ decision recorded for only 1 in 5 very sick hospitalized older patients, study finds

14 Sep, 2021 | 08:40h | UTC

‘Do not resuscitate’ decision recorded for only 1 in 5 very sick older patients, study finds – News Medical

Original study: Do not attempt cardiopulmonary resuscitation (DNACPR) decisions for older medical inpatients: a cohort study – BMJ Supportive & Palliative Care

 

Study suggests mobile stroke units (ambulances with staff and a CT scanner that may enable faster thrombolysis) may improve outcomes for ischemic stroke patients.

12 Sep, 2021 | 21:41h | UTC

Prospective, Multicenter, Controlled Trial of Mobile Stroke Units – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Patients treated by mobile stroke units had better outcomes, according to study published in NEJM – University of Texas Health Science Center at Houston

 

Commentary on Twitter (video – click to view)

https://twitter.com/NEJM/status/1436690999426748416

 

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

10 Sep, 2021 | 05:37h | UTC

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial – Nature Medicine

News release: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University

Related:

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

The Lancet Series: Out-of-hospital cardiac arrest 2021.

9 Sep, 2021 | 09:07h | UTC

Homepage: Out-of-hospital cardiac arrest 2021 (free registration required for both articles)

Cardiopulmonary resuscitation in special circumstances

Brain injury after cardiac arrest

 

Commentary on Twitter (thread – click for more)

 

RCT: A Seven-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales was noninferior to a 14-days course.

9 Sep, 2021 | 09:03h | UTC

Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales. A randomized, controlled trial – Clinical Microbiology and Infection

 

Commentary on Twitter

 

Review: Management of severe traumatic brain injury in regions with limited resources.

9 Sep, 2021 | 08:56h | UTC

Management of severe traumatic brain injury in regions with limited resources – Brain Injury

 

Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.

7 Sep, 2021 | 21:51h | UTC

Summary: Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? – Cochrane Library

Original review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library

 

Supplement: Current Issues in Venous Thromboembolism.

7 Sep, 2021 | 21:36h | UTC

Homepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine

Editorial: Current issues in venous thromboembolism

A review of upper extremity deep vein thrombosis

Outpatient treatment of emergency department patients diagnosed with venous thromboembolism

Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery

Prophylaxis and treatment of COVID-19 related venous thromboembolism

Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients

Catheter-directed thrombolysis and mechanical intervention in deep venous thrombosis: what is the status after the ATTRACT trial?

Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients

Radiologic mimics of pulmonary embolism

A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment

 

Case series: COVID-19 mRNA vaccination leading to CNS inflammation.

7 Sep, 2021 | 10:49h | UTC

COVID-19 mRNA vaccination leading to CNS inflammation: a case series – Journal of Neurology

 

Cohort study: Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest.

7 Sep, 2021 | 10:41h | UTC

Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest – Intensive Care Medicine

 

Commentary on Twitter

 

Annual Update in Intensive Care and Emergency Medicine 2021 – Non-Covid articles.

7 Sep, 2021 | 10:43h | UTC

Advanced management of intermediate-high risk pulmonary embolism

Pathophysiology and clinical implications of the veno-arterial PCO2 gap

To prone or not to prone ARDS patients on ECMO

Management of acute metabolic acidosis in the ICU: sodium bicarbonate and renal replacement therapy

Acute kidney injury in ECMO patients

Monitoring and modifying brain oxygenation in patients at risk of hypoxic ischaemic brain injury after cardiac arrest

Measuring vitamin C in critically ill patients: clinical importance and practical difficulties—Is it time for a surrogate marker?

Still a place for aortic counterpulsation in cardiac surgery and patients with cardiogenic shock?

See also: Covid articles

 

Podcast: The Best of Liver Tests.

7 Sep, 2021 | 10:29h | UTC

#293 The Best of Liver Tests with Dr. Elliot Tapper – The Curbsiders

 

RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.

6 Sep, 2021 | 11:11h | UTC

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.